Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M9140 in Chinese Participants With Solid Tumors
NCT06806046Phase 1Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of precemtabart tocentecan in colorectal cancer (CRC), sponsored by Merck KGaA. Primary endpoints: Number of Participants With Dose Limiting Toxicities up to 21 days and Number of Participants with Treatment-Emergent Adverse Events up to 8 months. Started Dec 2024; status: active, not recruiting.
02
Drugs
precemtabart tocentecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06806046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06806046.